HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal Adenocarcinoma

Creative Commons LicenseCreative Commons Attribution 4.0 International

Files in This Item:
journal_pone_0152523.pdf7.52 MBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/61874

Title: Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal Adenocarcinoma
Authors: Sato, Daisuke Browse this author
Tsuchikawa, Takahiro Browse this author →KAKEN DB
Mitsuhashi, Tomoko Browse this author →KAKEN DB
Hatanaka, Yutaka Browse this author →KAKEN DB
Marukawa, Katsuji Browse this author
Morooka, Asami Browse this author
Nakamura, Toru Browse this author →KAKEN DB
Shichinohe, Toshiaki Browse this author →KAKEN DB
Matsuno, Yoshihiro Browse this author
Hirano, Satoshi Browse this author →KAKEN DB
Issue Date: 29-Mar-2016
Publisher: The Public Library of Science
Journal Title: PLoS ONE
Volume: 11
Issue: 3
Start Page: e0152523
Publisher DOI: 10.1371/journal.pone.0152523
Abstract: It has been clear that cancer-associated fibroblasts (CAFs) in the tumor microenvironment play an important role in pancreatic ductal adenocarcinoma (PDAC) progression. However, how CAFs relate to the patients' prognosis and the effects of chemoradiation therapy (CRT) has not been fully investigated. Tissue microarrays (TMAs) representing 167 resected PDACs without preoperative treatment were used for immunohistochemical studies (IHC) of palladin, alpha-smooth muscle actin (SMA), and podoplanin. Correlations between the expression levels of these markers and clinicopathological findings were analyzed statistically. Whole sections of surgical specimens from PDACs with and without preoperative CRT, designated as the chemotherapy-first group (CF, n = 19) and the surgery-first group (SF, n = 21), respectively, were also analyzed by IHC. In TMAs, the disease-specific survival rate (DSS) at 5 years for all 167 cases was 23.1%. Seventy cases (41.9%) were positive for palladin and had significantly lower DSS (p = 0.0430). alpha-SMA and podoplanin were positive in 167 cases (100%) and 131 cases (78.4%), respectively, and they were not significantly associated with DSS. On multivariable analysis, palladin expression was an independent poor prognostic factor (p = 0.0243, risk ratio 1.60). In the whole section study, palladin positivity was significantly lower (p = 0.0037) in the CF group (5/19) with a significantly better DSS (p = 0.0144) than in the SF group (16/22), suggesting that stromal palladin expression is a surrogate indicator of the treatment effect after chemoradiation therapy.
Rights: http://creativecommons.org/licenses/by/4.0/
Type: article
URI: http://hdl.handle.net/2115/61874
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 土川 貴裕

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University